Professor Christopher Nutting
Consultant Clinical Oncologist BSc MBBS MD PhD FRCP FRCR MedFIPEM
Specialism: Head and neck, Radiotherapy, Thyroid
Available at: Cavendish, Chelsea, Sutton
- head and neck cancer
- thyroid cancer
Professor Nutting has both a private and an NHS practice at The Royal Marsden. He qualified from Portsmouth Grammar School in 1986 and from University College and Middlesex Hospital School of Medicine (University of London) in 1992.
He was awarded 1st Class BSc Honours (Medicine and Cell Pathology, University of London) in 1989 and MBBS (University of London) in 1992. He became a Member of the Royal College of Physicians (UK) in 1995 and Fellow of the Royal College of Radiologists (UK) in 1998. He was awarded Certification of European Society of Medical Oncology in 1999.
He undertook a period of study at Imperial College Business School and was awarded the Advanced Certificate in Health Care Management (University of London) in 2000. He studied for a Medical Doctorate (MD) at The Institute of Cancer Research, University of London, between 1998 and 2001 and was awarded MD in 2001.
He was appointed Consultant Clinical Oncologist at The Royal Marsden and Honorary Senior Lecturer in Clinical Oncology at The Institute of Cancer Research in 2001. He was appointed Teacher at the University of London and Head of the Head and Neck Unit at The Royal Marsden in 2002.
He was appointed National Clinical Lead in Head and Neck Cancer by the Department of Health (UK) and the Cancer Services Collaborative in 2003. Since 2003 he has been a member of the National Cancer Research Institute Committee (NCRI) for head and neck cancer research and became Chairman of this group in 2006. In 2007 he became President of the British Oncological Association, and was elected Honorary Faculty member at The Institute for Cancer Research.
He is Principal Investigator for a number of research trials including the Cancer Research UK sponsored PARSPORT and COSTAR Trials. He is principle or co-investigator on an additional 15 trials in head and neck cancer sponsored by The Royal Marsden or by the pharmaceutical industry.
He was appointed as National Clinical Oncology advisor to the Data for Head and Neck Oncology (DAHNO) project in 2005. He is Chairman of the National Advisory Board on Head and Neck Cancer to the Cancer Services Collaborative (DoH). He is holder of research grants for advancement of radiotherapy and chemotherapy research totalling approaching £1.5 million. He is a regular contributor to international medical publications and meetings, and has published over 100 articles in his areas of expertise.